Iranian Journal of Diabetes and Obesity

en Antibody Engineering Toward Enhancement of Teplizumab Anti-CD3 Binding Affinity in Type 1 Diabetes Prevention and Treatment تخصصي Special پژوهشي Research Objective: The monoclonal antibodies with CD3 target have the potential to change the progression of type 1 diabetes (T1D) and enhance the longevity of beta-cell function. The main objective of the study is antibody engineering toward Enhancement of Teplizumab Anti-CD3 Binding Affinity in T1D prevention and treatment. Materials and Methods: We aimed at finding the important amino acids of this antibody, and then replaced these amino acids with others to improve their binding affinity, and examine the binding affinity of antibody variants to antigens. In the end, we selected high-affinity variants of the antibody according to results of High Ambiguity Driven biomolecular DOCKing (HADDOCK). Results: Our research indicated that 14 mutated variants were able to enhance the binding characteristics of Ab in comparison to standard antibodies. Conclusion: The altered antibodies could serve as promising options for enhanced affinity binding to antigens, which could affect the specificity and sensitivity of antibodies.   Teplizumab, Antibody Engineering, Type 1 diabetes 97 109 http://ijdo.ssu.ac.ir/browse.php?a_code=A-10-30-445&slc_lang=en&sid=1 Fateme Sefid 0000-0003-0867-9305 No Department of Medical Genetics, Shahid Sadoughi University of Medical Science, Yazd, Iran. Department of Molecular Medicine,School of Advanced Technologies in Medicine,Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Research Center for Health Technology Assessment and Medical Informatics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Kimia Monshizadeh 0000-0003-2181-4890 No Department of Medical Genetics, Shahid Sadoughi University of Medical Science, Yazd, Iran. Research Center for Health Technology Assessment and Medical Informatics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Roya Ghenaatzadeh 0009-0000-4836-2375 No Research Center for Health Technology Assessment and Medical Informatics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Department of lmmunology, Faculty of Medicine, Shahid sadoughi University of Medical Sciences and Health Services, Yazd, Iran. Zahra Roodgarpour 0009-0006-0852-8143 No Research Center for Health Technology Assessment and Medical Informatics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Department of lmmunology, Faculty of Medicine, Shahid sadoughi University of Medical Sciences and Health Services, Yazd, Iran. Ghasem Azamirad 0000-0001-9323-1294 No Department of Mechanical Engineering, Yazd University, Yazd, Iran. Hamid Mirhosseini 0000-0002-3505-109X Yes Research Center for Health Technology Assessment and Medical Informatics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.